16.99
-0.26(-1.51%)
Currency In USD
| Previous Close | 17.25 |
| Open | 16.93 |
| Day High | 17.36 |
| Day Low | 16.8 |
| 52-Week High | 23 |
| 52-Week Low | 11.09 |
| Volume | 171,924 |
| Average Volume | 251,366 |
| Market Cap | 455.63M |
| PE | -65.35 |
| EPS | -0.26 |
| Moving Average 50 Days | 16.13 |
| Moving Average 200 Days | 16.82 |
| Change | -0.26 |
If you invested $1000 in Eton Pharmaceuticals, Inc. (ETON) since IPO date, it would be worth $2,718.4 as of March 01, 2026 at a share price of $16.99. Whereas If you bought $1000 worth of Eton Pharmaceuticals, Inc. (ETON) shares 5 years ago, it would be worth $2,084.66 as of March 01, 2026 at a share price of $16.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
GlobeNewswire Inc.
Feb 25, 2026 6:47 PM GMT
DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to b
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
GlobeNewswire Inc.
Feb 20, 2026 11:50 AM GMT
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
GlobeNewswire Inc.
Feb 02, 2026 11:50 AM GMT
Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused